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Abstract Recently, a low creatinine clearance (CrCl) of
<65 ml/min was described as a new signiﬁcant and
independent risk factor for the number of fallers and
falls in a community-dwelling elderly population. In this
study we investigated if a low creatinine clearance of
<65 ml/min is also a risk factor for falls and fractures in
elderly men and women treated for osteoporosis. In a
cross-sectional study with the help of questionnaires we
assessed the prevalence of having experienced falls
within the last 12 months according to renal function in
5,313 German men and women receiving treatment for
osteoporosis. The CrCl was calculated using the estab-
lished Cockcroft-Gault formula. The prevalence of falls
and fractures was assessed in multivariate-controlled
logistic regression models according to a CrCl cut oﬀ of
65 ml/min. The P -values were two-sided. In this study
of elderly men and women treated for osteoporosis
(n=5,313), 60.9% (n=3,238) had a CrCl of <65 ml/
min, which was associated in multivariate controlled
analyses, compared to a CrCl of ‡65 ml/min (n=2,075),
with a signiﬁcant increased risk of experiencing falls
(1,775/3,238 vs. 773/2,075, OR 1.69, 95% CI 1.50–1.91,
P<0.0001) and an increased risk for multiple falls (37.1
vs. 22.6%, OR 1.63, 95% CI 1.42–1.87, P<0.0001).
Furthermore, compared to a creatinine clearance of
‡65 ml/min, a creatinine clearance of <65 ml/min was
also associated with a signiﬁcant increased multivariate
controlled risk for hip fractures (OR 1.57, 95%CI 1.18–
2.09, P=0.002), for radial fractures (OR 1.79, 95%CI
1.39–2.31, P=<0.0001), for total vertebral fractures
(OR 1.31, 95%CI 1.19–1.55, P=0.003) and for fall-
associated vertebral fractures (OR 1.24, 95% CI 1.03–
1.54, P=0.031). Similar to community-dwelling elderly,
in elderly men and women treated for osteoporosis a
CrCl of less than 65 ml/min is a signiﬁcant and inde-
pendent risk factor for falls. Furthermore, we could
show for the ﬁrst time that a low creatinine clearance in
elderly men and women treated for osteoporosis is also
associated with a signiﬁcantly increased risk of vertebral,
hip and radial fractures.
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Introduction
Recently, a low creatinine clearance of <65 ml/min was
described as a new and independent risk factor for falls
in elderly community-dwelling men and women [1]. It
could be shown in another recently published study that
the low creatinine clearance associated increased risk of
falls, and increased number of fallers can eﬀectively be
treated with alfacalcidol, a synthetic D-hormone pro-
drug [2]. The observed eﬀect of alfacalcidol on the
number of falls and fallers observed in participants with
a creatinine clearance of <65 ml/min is most probably
due to increased D-hormone levels in the serum or at the
target organ’s muscles and nerves, which have been
associated with an increase of muscle strength [3, 4, 5]
and neuromuscular coordination [5, 6], improved bal-
ance [7] and increased functional mobility [8, 9]. The
conversion of calcidiol [25(OH)D3] to the metabolically
most active form of vitamin D, the D-hormone [calcit-
riol; 1, 25(OH)2 D3] is highly dependent on the creati-
nine clearance [10, 11, 12]. Even a slight decrease in
D-hormone and a corresponding slight increase in iPTH
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serum levels, observed when creatinine clearance (CrCl)
decreases to 60–80 ml/min [13], is associated with sub-
clinical myopathy and balance trouble [3, 4, 14, 15].
It is nowadays accepted that an increased occurrence
of falling among men and women suﬀering from oste-
oporosis together with increased skeletal fragility has a
larger eﬀect on the increased frequency of fractures than
bone mass alone [16, 17]. At least 90% of all hip frac-
tures are due to an age-related decline in muscle strength
and increased bone fragility, which are both strongly
associated with an increase in falls [18]. The currently
published updated Kidney Disease Outcomes Quality
Initiative practice guidelines by the US Kidney Foun-
dation (K/DOQI) [19] mention that a slight decrease of
the CrCl is associated with a decrease in bone mineral
density [20], and since a CrCl below 60 ml/min increases
the risk of fractures signiﬁcantly, the guidelines suggest
an intensive control of patients with decreased creatinine
clearance [19]. A low creatinine clearance associated
with increased risk of falls and fallers in osteoporotic
men and women, which could easily be treated with
D-hormone, would have a tremendous impact on the
prevention of osteoporotic fractures. To test our
hypothesis that a low creatinine clearance is also a risk
factor for falls in osteoporotic patients, we investigated
if a low creatinine clearance of <65 ml/min is associated
with an increased risk of falls and risk to become a faller
in an elderly population of German men and women
treated for osteoporosis.
Subjects and methods
This study is a cross-sectional analysis of a German
study that was conducted from May 2002 till March
2003. The aim of this study was to assess the association
between osteoporosis and renal function in osteoporotic
German women and men aged 65 and older. Therefore
GPs, specialists in internal medicine and orthopedists
involved in the treatment of osteoporotic patients were
asked to ﬁll in a questionnaire concerning their patients
treated for osteoporosis. Four hundred ﬁfty-ﬁve medical
centers from all over Germany participated in this study.
The questionnaire had to be ﬁlled out in the presence
and with the help of the patient treated for osteoporosis
at a medical visit during the study time period.
The questionnaire gave information on some demo-
graphic and, if available, laboratory parameters as well
as parameters of osteoporosis and falls. Demographic
parameters included gender, age, weight, height and
intake of some speciﬁc long-term medication [immuno-
suppressive therapy (no speciﬁcation), corticosteroids,
anticoagulants (oral/parenteral) and vitamin D and
calcium]. Laboratory parameters included serum levels
of creatinine, calcium and phosphate. Alkaline phos-
phatase, calcidiol, calcitriol, and iPTH serum levels as
well as C-reactive protein (CRP) were available only for
a tiny minority of participants. Creatinine clearance was
calculated using the well-established formula from
Cockcroft-Gault, adjusted for gender [21]. The Cockr-
oft-Gault formula is widely accepted and used for the
calculation of the creatinine clearance. However, it gives
only an estimate of the GFR as compared to a direct
measurement of the GFR with 24-h urine sampling or
inulin clearance. Parameters of osteoporosis included
the exact date of the diagnosis of osteoporosis (DD/
MM/YY), the tools used for the diagnosis of osteopo-
rosis (clinical investigation, X-ray, DEXA, ultrasound
or laboratory) as well as anti-osteoporotic treatment
[biphosphonates (yes/no), ﬂuoride (yes/no), raloxifen
(yes/no), alfacalcidol (yes/no) and others (yes/no, with
speciﬁcation, i.e., calcium or vitamin D alone)]. The
duration, dosage of anti-osteoporotic treatment and
possible switches of therapy were not assessed. The
diagnostic criteria for osteoporosis used by the physician
were not assessed. Therefore, in this study the diagnosis
of osteoporosis was solely based on the physician’s re-
port. Assessment of falls and frequency of falls was
based on recall of the past 12 months. Parameters for
falls and fractures included the number of falls and
fractures during the last 12 months, experience of pain
(muscle pain/pain in the bone), pain severity (heavy,
medium, light), localization of a possible fracture (ver-
tebral, hip, radius, other) and the question if the frac-
ture(s) were associated to osteoporosis. Falls were not
deﬁned, and the participating physicians were not
trained in the assessment of falls. Fracture incidence
within the last 12 months was assessed as documented in
the medical history of each individual participant and
not based on the patient’s recall. The Data, Safety and
Monitoring Board established by GWD Consult Ger-
many (Safety and Monitoring Board: GWD Consult,
Research Contract, Postfach 1210, 63152 Mu¨lheim/
Main, Germany) reviewed the study.
The main follow-up multivariate analysis compared
the number of fallers and falls in the two groups
according to the cutoﬀ value for creatinine clearance set
at 65 ml/min. The multivariate diﬀerence in the number
of fallers and falls between groups is given as odds ratio
(OR) with 95% conﬁdence intervals (CI). We also
assessed the number of fractures according to the CrCl.
For the main analyses we used ANCOVA and pooled
linear regression models to control simultaneously for
several potentially confounding variables. Comparisons
of means were performed by multivariate adjusted anal-
yses of variance [22]. Since age and BMI distributions
were markedly skewed, logarithmic transformation of
these variables was performed prior to analyses. The
multivariate analyses included predictors that have been
previously shown to be associated with an increased risk
of falling or variables that were signiﬁcantly diﬀerent
between treatment groups. These covariates were gender
(male, female), age and body mass index (BMI). In the
main analyses we used only laboratory variables that
were available for all participants. These variables
were serum levels of creatinine, calcium and phosphate.
Age, BMI and creatinine clearance were analyzed
as continuous variables as well as categorical variables
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[age categories: younger than 65 (n=149), 65–69
years (n=1,513), 70–74 years (n=1,383), 75–79 years
(n=1,099), 80–84 years (n=788), 85 and older (n=435)/
BMI categories: <19 kg/m2 (n=125), 19–24 kg/m2
(n=2,104), 25–29 kg/m2 (n=2,382), 30 kg/m2 and more
(n=756)]. For all other analyses we used the t -test,
Wilcoxon rank sum test and chi-square.
Since according to recently published data [1] a cre-
atinine clearance of <65 ml/min has been found to be
signiﬁcantly associated with decreasing D-hormone
serum levels and a signiﬁcantly increased risk of falls in
community-dwelling elderly men and women, we also
set the threshold for creatinine clearance at 65 ml/min in
this study. A 5% signiﬁcance level was maintained
throughout these analyses, and all tests were two-sided.
The statistical analyses were conducted using the SAS
statistical software package, version 8.2, by the SAS
Institute Inc., Cary, N.C., licensed to the University of
Basel, Switzerland.
Results
General
Participating in this study were 5,481 German men and
women treated for osteoporosis. Of them, 168 were de-
leted from the analyses because of missing values for the
main outcome variable (creatinine, res. creatinine
clearance) or missing values for gender, age or BMI.
From the 5,313 included participants, 1,067 (20.1%)
were men and 4,246 (79.9%) were women. The mean age
was 74.0 years. Men were signiﬁcantly younger (mean
age: 73.0±6.6 vs. 74.2±7.3 years, P<0.0001) and had a
signiﬁcantly higher BMI than women (26.3±3.6 kg/m2
vs. 25.9±4.0 kg/m2, P=0.029)
Concerning the speciﬁc long-term medical treatment
assessed in this study, 7.2% (n=380) had had long-term
immunosuppressive therapy, 23.3% (n=1,236) had re-
ceived long-term therapy with glucocorticoids, 16.5%
(n=875) were under treatment with anticoagulants and
56.9% (n=3,025) had received long-term therapy with
vitamin D and calcium. Signiﬁcantly more women than
men in this study group were under these speciﬁc long-
term therapies (women vs. men: immunosuppressive
therapy 5.4 vs. 1.8%, P=0.026/corticosteroids: 17.1 vs.
6.2%, P<0.0001/anticoagulants: 11.8 vs. 4.7%,
P<0.0001/vitamin D and calcium: 47.6 vs. 9.3%,
P<0.0001). Concerning anti-osteoporotic treatment,
31.7% of the participants were treated with bipho-
sphonates, 12.4% with ﬂuorides, 3.9% with raloxifen,
29.3% with alfacalcidol and 3.6% received another
treatment. For 19.1% of the participants, we have no
speciﬁcation about the anti-osteoporotic treatment.
Laboratory
The mean creatinine clearance in the participants of this
study was 59.4±23.3 ml/min. Men had a signiﬁcantly
higher creatinine clearance than women (men vs. wo-
men: 67.2±23.5 vs. 57.5±22.8, P<0.0001). Of the
participating osteoporotic men and women, 60.9% were
found to have creatinine clearance of <65 ml/min
(3,328/5,313 vs. 2,075/5,313).
Participants with a creatinine clearance of <65 ml/
min as compared to participants with a creatinine
clearance of ‡65 ml/min were signiﬁcantly more prone to
be of female gender (women vs. men: 64.4 vs. 35.6%,
P<0.0001), were signiﬁcantly older (76.0±6.2 vs.
70.8±7.04 years, P<0.0001, controlled for gender) and
had a signiﬁcantly lower BMI (25.1±3.3 kg/m2 vs.
27.5±4.0 kg/m2, P<0.0001, controlled for gender)
(Table 1).
As compared to participants with a creatinine clear-
ance of ‡65 ml/min, participants with a creatinine
clearance of <65 ml/min were signiﬁcantly more prone
to be treated with anticoagulants (17.8 vs. 14.5%,
P=0.002) (Table 1). For all other variables we found no
signiﬁcant diﬀerences between groups according to cre-
atinine clearance.
Association between creatinine clearance and number of
fallers and number of falls
The multivariate analyses included predictors that
have been previously shown to be associated with an
increased risk of falling and that were available or
variables that were signiﬁcantly diﬀerent between treat-
ment groups. These variables were: age, gender, body
mass index (BMI), treatment with anticoagulants and
Table 1 Comparison of the
characteristics of the study
participants with a creatinine
clearance of <65 ml/min vs.
‡65 ml/min. *BMI body mass
index, +controlled for gender
Categories CrCl <65 ml/min CrCl ‡65 ml/min P-value
(n=3,238) (n=2,075)
Gender (number) Male/female 35.6%: 64.4% 52.7%: 47.3% <0.0001
Age (mean ± SD) Years 76.0±6.2 70.8±7.0 <0.0001+
BMI* (mean ± SD) kg/m2 25.1±3.3 27.5±4.0 <0.0001+
Long-term medication (in %)
Glucocorticoid therapy 24.2% 21.9% 0.056
Anticoagulant therapy 17.8% 14.5% 0.002
Immuno-suppressive therapy 7.4% 6.8% 0.359
Vitamin D and calcium 56.7% 57.4% 0.626
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glucocorticoids and total number of the daily intake of
assessed medication. In this population, anti-osteopo-
rotic treatment was not a signiﬁcant predictor for falls.
The elderly men and women treated for osteoporosis
with a creatinine clearance of <65 ml/min had a sig-
niﬁcantly higher risk of falls (1,775 falls in 3,238 par-
ticipants vs. 773 falls in 2,075 participants; OR 1.69,
95% CI 1.50–1.91, P<0.0001) in multivariate controlled
analyses compared to the participants with a creatinine
clearance of ‡65 ml/min (Table 2). As compared to a
CrCl of ‡65 ml/min a low CrCl of <65 ml/min was also
associated with a signiﬁcantly increased risk of being a
frequent faller (% of frequent fallers according to CrCl:
<65 ml/min vs. ‡65 ml/min 37.1% vs. 22.6%, OR 1.63
95% CI 1.43–1.87, P<0.0001) (Table 2). Other signiﬁ-
cant variables associated with the risk for falls were age
(P<0.0001) and the number of medications (P=0.006).
Gender or BMI were not signiﬁcant predictors for falls
in this study (P=0.29 res. P=0.078).
Association between creatinine clearance, number of
fallers and fractures
Compared to participants with a CrCl of ‡65 ml/min,
participants with a CrCl of <65 ml/min had a multi-
variate-adjusted signiﬁcantly higher incidence of femur
fractures (253/3,238 vs. 78/2,075, OR 1.57, 95%CI 1.18–
2.09, P=0.002), a general signiﬁcantly higher incidence
of vertebral fractures (607/3,238 vs. 268/2,075, OR 1.31,
95%CI 1.10–1.55, P>0.0001), a signiﬁcantly higher
incidence of fall associated vertebral fractures (490/1,775
vs. 181/773, OR 1.24, 95%CI 1.03–1.54, P=0.031) and a
signiﬁcantly higher incidence of radial fractures (285/
3,238 vs. 104/2,075, OR 1.79, 95%CI 1.39–2.31,
P<0.0001) (Table 2 and Fig. 1).
Association between creatinine clearance, number of
falls and long-term medication
Participants with a creatinine clearance of <65 ml/min
and with no long-term medication had an increased risk
for falls compared to participants with a creatinine
clearance of ‡65 ml/min and no long-term medication
(OR 1.78, 95% CI 1.55–2.05, P<0.0001).
For participants with long-term glucocorticoid
treatment, a low creatinine clearance of <65 ml/min
cumulatively increased the risk for falls: OR for falls in
participants with a low CrCl of <65 ml/min and long-
term glucorticoid treatment compared to participants
with a CrCl of ‡65 ml/min and no long-term glucocor-
ticoid treatment: OR 2.57, 95% CI 2.16–3.01/OR for
falls in participants with low CrCl of <65 ml/min and
long-term glucocorticoid treatment compared to par-
ticipants with a CrCl of ‡65 ml/min and a long-term
glucocorticoid treatment: OR 1.65, 95%CI 1.31–2.07/
OR for falls in participants with a CrCl of ‡65 ml/min
and a long-term glucorticoid treatment compared to
participants with a CrCl of ‡65 ml/min and no long-
term glucocorticoid treatment: OR 1.50, 95% CI
Fig. 1 Percentage of fractures
(fx) at diﬀerent sites within the
last 12 months in elderly men
and women treated for
osteoporosis according to a
creatinine clearance of <65 ml/
min vs. a creatinine clearance of
‡65 ml/min
Table 2 Multivariate OR for number of falls and frequent fallers
and number of fractures at diﬀerent sites in elderly men and women
treated for osteoporosis according to a creatinine clearance of
<65 ml/min vs. a creatinine clearance of ‡65 ml/min + adjusted
for age, gender, BMI, long-term treatment with anticoagulants and
glucocorticoids and total number of long-term medications. OR§
odds ratio, CIII conﬁdence interval
Parameter Multivariate
adjusted+ OR§
(95% CIII)
P-value
Falls 1.69 (1.50–1.91) <0.0001
Frequent fallers 1.63 (1.42–1.87) <0.0001
Fractures
Fracture of the femur 1.57 (1.18–2.09) 0.002
Fracture of the radius 1.79 (1.39–2.31) <0.0001
Vertebral fractures (total) 1.31 (1.10–1.55) 0.003
Vertebral fractures
(fall associated)
1.24 (1.03–1.54) 0.031
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1.28–1.74, P for trend <0.001. Similar results were
found for frequent fallers as well as for the other as-
sessed long-term medications (OR for falls in partici-
pants with a CrCl of <65 ml/min and a long-term
anticoagulant therapy compared to participants with a
CrCl of ‡65 ml/min and a long-term anticoagulant
therapy: OR 1.56, 95% CI 1.15–2.12, P=0.005/OR for
falls in participants with a CrCl of <65 ml/min and a
long-term vitamin D and calcium supplementation
compared to participants with a CrCl of ‡65 ml/min and
a long-term vitamin D and calcium supplementation:
OR 1.91, 95% CI 1.62–2.27, P<0.0001/OR for falls in
participants with a CrCl of <65 ml/min and a long-term
immuno-suppressive therapy compared to participants
with a CrCl of ‡65 ml/min and a long-term immuno-
suppressive therapy: OR 2.46 95% CI 1.54–3.92,
P=0.0002).
Association between creatinine clearance, number
of fractures and long-term medication in participants
experiencing falls
A history of no long-termmedication in participants with
a low CrCl <65 ml/min as compared to participants
with a CrCl of ‡65 ml/min was associated with an
increased risk for radial fractures (OR 1.37 95% CI 1.01–
1.84, P=0.040) and no signiﬁcant diﬀerences for other
fracture sites. A long-term immunosuppressive therapy
and a history of falls in participants with a low
CrCl <65 ml/min compared to participants with a CrCl
of ‡65 ml/min was associated with an increased risk
for vertebral fractures (OR 3.02 95% CI 1.31–6.96,
P=0.009) and no signiﬁcant diﬀerences for other fracture
sites. A long-term therapy with vitamin D and calcium
and a history of falls in participants with a low
CrCl <65 ml/min compared to participants with a CrCl
of ‡65 ml/min was associated with an increased risk for
radial fractures (OR 1.59, 95% CI 1.08–2.32, P=0.019)
and no signiﬁcant diﬀerences for other fracture sites.
In participants with a long-term anticoagulant or
corticoid therapy, we found no diﬀerences in the number
of fractures in participants who fell according to creat-
inine clearance.
Discussion
Similar to community-dwelling elderly, we found that
elderly men and women treated for osteoporosis and with
a low creatinine clearance of <65 ml/min have a signif-
icantly increased risk of falls and a signiﬁcant increased
risk of frequent falls compared to elderly men and
women treated for osteoporosis and with a creatinine
clearance of ‡65 ml/min. Furthermore, a creatinine
clearance of <65 ml/min was compared to CrCl of
‡65 ml/min in these elderly men and women treated for
osteoporosis associated with a signiﬁcant increased risk
of total vertebral fractures, with a signiﬁcant increased
risk of fall-associated vertebral fractures and with a sig-
niﬁcant increased risk of hip and radial fractures. The
fact that hip and radius fractures are mainly fall-induced
is accepted world-wide [18] and has been conﬁrmed, but
our result that vertebral fractures are also partly induced
by falls is new and to our knowledge has never been
described in the literature. A low creatinine clearance of
<65 ml/min together with long-term therapies such as
glucocorticoid, immunosuppressive and anticoagulant
treatments, which have been previously described as
increasing the risk of osteoporosis [23, 24, 25, 26], in-
creases the risk for falls and fractures cumulatively in
these elderly men and women treated for osteoporosis.
The incidence of falls and fractures increases rapidly after
the ﬁrst 3 months and reverts sharply towards baseline
after discontinuation of oral glucocorticoid treatment
[23]. Immunosuppressive drugs are given to patients with
chronic inﬂammatory diseases. In these diseases circu-
lating cytokines interfere with bone and muscle metab-
olism and induce a signiﬁcant risk for secondary
osteoporosis, muscle atrophy and fractures [27, 28, 29].
Interestingly, in this study group a long-term therapy
with vitamin D and calcium was not associated with a
decreased risk for falls in participants with a low creati-
nine clearance of <65 ml/min, but was contrarily asso-
ciated with an increased risk for falls and an increased
risk for radial fractures. However, this result should be
interpreted with caution since we don’t have any data on
the amount and the duration of the supplementation of
calcium and vitamin D and no information on compli-
ance, i.e., measured as calcidiol serum levels. In a recently
published, randomized, double-blind placebo-controlled
study in the elderly aged over 80 years it has been shown
that a single oral dose of 300,000 IU plain vitamin D
over 6 months failed to reduce the fall rate, even in those
who were vitamin D deﬁcient (<12 ng/ml) at baseline
and after normalization of the 25(OH)D levels [30]. A
conﬁrmative, placebo-controlled clinical study including
10,000 community-dwelling elderly women and men has
recently proven that an annual intramuscular application
of 300,000 IU plain vitamin D is not able to reduce the
risk of falls and hip or other non-vertebral fractures [31].
However, in another study the supplementation of vita-
min D and calcium was found to signiﬁcantly reduce the
number of falls in institutionalized elderly women with
vitamin D deﬁciency [50]. All these ﬁndings support our
theory that below a creatinine clearance of <65 ml/min,
calcidiol is not metabolized to calcitriol, the most active
form of vitamin D. In a signiﬁcant number of osteopo-
rotic people, even with normal vitamin D serum levels
(>12 ng/ml), a deterioration of renal function, easily
measurable as deterioration of the creatinine clearance,
leads to decreased activity of the renal 1a-hydroxylase
[10, 32] and consecutively to lowD-hormone serum levels
[33, 34, 35], as observed in age-related impaired renal
function [20], with drug interaction (i.e., glucocorticoid
and immunosuppressive treatment) or in chronic
inﬂammatory diseases. Nuclear factor jB (NFjB)
and tumor necrosis factor (TNF)-a inhibit the renal
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1a-hydroxylation of 25(OH)D [36], which explains the
decreased serum concentration of D-hormone in chronic
inﬂammatory diseases depending on disease activity [37].
D-hormone has a scientiﬁcally established eﬀect on
muscle strength, balance and functional mobility [3, 4, 5,
6, 7, 8, 9]. In several studies [38, 39] the eﬀect of D-
hormone treatment (alfacalcidol res. calcitriol) on the
risk of falls has been proven. Furthermore, it has been
shown that treatment with alfacalcidol in community-
dwelling elderly men and women with a low CrCl of
<65 ml/min signiﬁcantly decreases the low CrCl-asso-
ciated high risk for falls [2]. The increased osteopenia and
osteoporosis observed with low creatinine clearance
by other authors [19, 20] may also be due to the low
D-hormone serum levels observed with a creatinine
clearance of<65 ml/min. Our result enhances the theory
suggested by other studies [4, 5, 6, 7, 32, 34, 35, 40, 41, 42]
that low D-hormone is an independent risk factor for
falls [5, 38, 39, 42] and that D-hormone is directly in-
volved in the causal pathogenic pathway of decreased
muscle strength related falls [9, 43, 44, 45].
Histochemical classiﬁcation of the muscle ﬁber com-
position based on muscle biopsies revealed that a
treatment of osteoporotic patients with alfacalcidol
(1 lg daily) for 3 to 6 months induced a signiﬁcant in-
crease in the relative number of fast-twitch type II ﬁbers
[9]. In addition there was an increase in the cross-sec-
tional area of this muscle ﬁber type that is responsible
for fast reaction and which is decreased in older age [9].
D-hormone receptors (VDRs) have been found in
skeletal muscles and nerves [46] through which muscle
contraction and relaxation are controlled by the inﬂux
and eﬄux of calcium and in addition the muscle protein
synthesis [43]. It has been recently conﬁrmed in VDR
gene-deleted mice that the absence of VDRs causes a
reduction of skeletal muscle ﬁber size based on an
increased expression of myogenic regulation factors
(Myf5, myogenin, E2A) through which the strictly reg-
ulated diﬀerentiation and maturation of muscle cells are
disturbed [45]. The muscular abnormalities are inde-
pendent from secondary, metabolic changes, e.g., hypo-
calcemia or hyperparathyroidism. This conﬁrms the
direct eﬃcacy of VDRs. The fact that a treatment with
D-hormone of VDR-positive myoblasts in vitro down-
regulates the mentioned myoregulating transcription
factors points out in addition the important role of
D-hormone and VDRs in muscle development [45].
Older age is signiﬁcantly associated with decreased VDR
expression in human skeletal muscle tissue [47], and a
positive correlation was found between femoral muscle
strength and function and D-hormone serum levels in the
elderly [4, 8]. These results suggest that the age-related
decline in muscle strength and function and the increase
of falls could be explained in part by a decrease of VDRs
and a decrease of D-hormone in serum and/or at the
receptor level.
We therefore conclude that our observed increased
risk of falls in elderly men and women treated for
osteoporosis with a low creatinine clearance of <65 ml/
min is due to a creatinine clearance-dependent decrease
in D-hormone serum levels. Our ﬁnding that a long-term
treatment with vitamin D and calcium in osteoporotic
men and women with a CrCl of <65 ml/min is associ-
ated with an increased risk for falls suggests that the
only treatment option for osteoporotic men and women
with a low CrCl of <65 ml/min, in order to prevent falls
and fall-associated fractures and in order to treat the
metabolic low D-hormone syndrome, are D-hormone
analogs such as calcitriol or alfacalcidol. The rationale
for this conclusion is the accepted scientiﬁc knowledge
that D-hormone analogs can act without metabolic
activation in the kidney, which results in higher con-
centrations of D-hormone at the receptors of the target
organs [48]. The diﬀerence between plain vitamin D and
D-hormone analogs on low creatinine clearance-related
falls can be explained by the known fact that the
expression of D-hormone receptor occurs only in the
presence of D-hormone, not in the presence of plain
vitamin D. It can be hypothesized that an increased
expression of the D-hormone receptors in the muscle, in
neurons and in the brain leads to an improvement of
muscle power and an improvement of fall-related neu-
ronal functions, e.g., increased balance performance,
increased muscle coordination and increased cognitive
capabilities, which all would result in a reduction of
falls. Serum levels of calcitriol, but not of calcidiol, have
been found to be signiﬁcantly correlated with cognitive
function in elderly women [49].
We furthermore found that elderly men and women
treated for osteoporosis with long-term treatments
known to increase the risk of osteoporotic fractures,
such as long-term treatment with immuno-suppressive
therapy, long-term corticosteroid treatment and long-
term anticoagulant treatment, are at greater risk for falls
and fractures when these long-term treatments are
combined with a low CrCl of <65 ml/min. Physicians
should therefore pay special attention to patients with
such long-term treatment and assess the creatinine
clearance in order to diagnose high risk patients for falls
and fractures and treat them accordingly.
Our study has several limitations. The results are from
a cross-sectional study with its well-known limitations of
interpretation. The primary outcome variable ‘‘falls’’ was
assessed by recall with the inherent recall bias. Another
limitation is that falls were not deﬁned, and physicians
were not instructed in the assessment of falls. Therefore,
we cannot rule out some miss-classiﬁcation in the out-
come variable falls, in the sense that some non-locomo-
toric extrinsic falls [i.e., due to some speciﬁc physical
activities (skiing, cycling) or accidents (being run over by
a dog or child)] or due to syncopal falls were assessed as
locomotoric intrinsic falls. However, we assume that the
incidence of extrinsic or syncopal falls is independent
from creatinine clearance and does not inﬂuence the
validity of our result. Concerning the fall-associated
fractures, we also did not assess the history of fractures,
which would have been an important control variable for
this outcome variable. We could also not control for
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other important covariates such as comorbid conditions,
number of medications, physical activity and other not-
assessed control variables. Therefore, we cannot rule out
uncontrolled confounding. Furthermore, the diagnosis
of osteoporosis was solely based on the physician’s
report. We can therefore not rule out a misclassiﬁcation
concerning the diagnosis of osteoporosis. We can assume
that this possible misclassiﬁcation concerns the whole
study group and does not inﬂuence our result on the
inﬂuence of a low creatinine clearance on the frequency
of falls and fractures in this population. The participants
were Caucasian elderly men and women over the age of
65 treated for osteoporosis. The diagnosis of osteopo-
rosis was not based on BMD for all participants.
Therefore, our ﬁndings cannot be generalized to a
general osteoporotic population, to a younger popula-
tion or to osteoporotic men and women of other races.
In conclusion, in this observational study a low cre-
atinine clearance of <65 ml/min in elderly men and
women treated for osteoporosis was associated with an
increased risk of falls, an increased risk of frequent falls
and an increased risk of total vertebral fractures, fall-
associated vertebral fractures, hip and radial fractures.
Randomized controlled studies are needed to conﬁrm
our ﬁndings.
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